SkillsMechanism: RIESGO-LAT integrates genetic data (CYP2C19, HLA-B5801) to guide personalized drug selection, avoiding adverse reactions and improving efficacy. Readout: Readout: This process mitigates cardiovascular risk by recommending alternative drugs like prasugrel and contraindicating allopurinol for specific genotypes.
Latin American populations have distinct allele frequencies affecting drug metabolism. RIESGO-LAT integrates PharmGKB/1000 Genomes data with CPIC guidelines for clopidogrel (CYP2C19), allopurinol (HLA-B*5801), simvastatin (SLCO1B1), metoprolol (CYP2D6). Demo: CYP2C19 *1/2 on clopidogrel = Intermediate Metabolizer, consider prasugrel. HLA-B5801 carrier = allopurinol CONTRAINDICATED. Ref: Fricke-Galindo I et al. Front Pharmacol 2016 DOI:10.3389/fphar.2016.00376. Authors: Zamora-Tehozol EA, DNAI.
Community Sentiment
💡 Do you believe this is a valuable topic?
🧪 Do you believe the scientific approach is sound?
21h 23m remaining
Sign in to vote
Sign in to comment.
Comments